WO2009008632A3 - Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis - Google Patents

Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis Download PDF

Info

Publication number
WO2009008632A3
WO2009008632A3 PCT/KR2008/003950 KR2008003950W WO2009008632A3 WO 2009008632 A3 WO2009008632 A3 WO 2009008632A3 KR 2008003950 W KR2008003950 W KR 2008003950W WO 2009008632 A3 WO2009008632 A3 WO 2009008632A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastritis
solubilized drug
gastroretentive system
therapeutic effect
stomach
Prior art date
Application number
PCT/KR2008/003950
Other languages
French (fr)
Other versions
WO2009008632A2 (en
Inventor
Moo-Hi Yoo
Jeong-Hoon Kim
Sun-Woo Jang
Jung-Woo Lee
Sang-Dug Han
Sung-Hyun Park
Original Assignee
Dong A Pharm Co Ltd
Moo-Hi Yoo
Jeong-Hoon Kim
Sun-Woo Jang
Jung-Woo Lee
Sang-Dug Han
Sung-Hyun Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd, Moo-Hi Yoo, Jeong-Hoon Kim, Sun-Woo Jang, Jung-Woo Lee, Sang-Dug Han, Sung-Hyun Park filed Critical Dong A Pharm Co Ltd
Publication of WO2009008632A2 publication Critical patent/WO2009008632A2/en
Publication of WO2009008632A3 publication Critical patent/WO2009008632A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is provided a gastroretentive system matrix formulation containing a compound represented by Formula 1 that has a therapeutic effect on gastritis and is solubilized in the stomach, and a method for preparing the gastroretentive system matrix formulation. The gastroretentive system matrix formulation according to the present invention may be useful to improve the solubility of a solubilized drug under an acidic condition in the stomach, and maximize an anti-inflammatory effect of the solubilized drug by increasing the retention time of the formulation in the stomach through the continuous release the solubilized drug into the stomach.
PCT/KR2008/003950 2007-07-06 2008-07-04 Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis WO2009008632A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0068368 2007-07-06
KR1020070068368A KR101381999B1 (en) 2007-07-06 2007-07-06 Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis

Publications (2)

Publication Number Publication Date
WO2009008632A2 WO2009008632A2 (en) 2009-01-15
WO2009008632A3 true WO2009008632A3 (en) 2009-03-12

Family

ID=40229250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/003950 WO2009008632A2 (en) 2007-07-06 2008-07-04 Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis

Country Status (2)

Country Link
KR (1) KR101381999B1 (en)
WO (1) WO2009008632A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253808A1 (en) * 2007-11-12 2009-10-08 Pharmaceutics International, Inc. Tri-molecular complexes and their use in drug delivery systems
US20110287096A1 (en) * 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
JP6891113B2 (en) * 2015-07-13 2021-06-18 協和発酵バイオ株式会社 Tablets high in arginine
CN106905280B (en) * 2017-02-24 2019-04-09 安徽医科大学 Hesperetin analog derivative that a kind of amide groups replaces and preparation method thereof and as the application in the drug of anti-alzheimer's disease
JP7458317B2 (en) 2017-10-31 2024-03-29 サムヤン、ホールディングス、コーポレーション Oral solid preparation composition with improved disintegration and method for producing the same
US11511093B2 (en) 2019-10-11 2022-11-29 Wonkwang University Center for Industry Academy Cooperation Gastroretentive drug delivery device having expandable structure and manufacturing method therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004541A1 (en) * 1996-07-25 1998-02-05 Dong A Pharmaceutical Co., Ltd. Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease
US6156343A (en) * 1994-12-27 2000-12-05 Akzo Nobel N.V. Controlled release preparation
US6475521B1 (en) * 1998-03-19 2002-11-05 Bristol-Myers Squibb Co. Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2005023244A1 (en) * 2003-09-04 2005-03-17 Dong-A Pharmaceutical Co., Ltd. 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof
KR20050098440A (en) * 2004-04-07 2005-10-12 동아제약주식회사 Rapid-acting oral formulation of artemisia extract using solid dispersion, processing method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100684099B1 (en) * 2005-06-30 2007-02-16 주식회사 씨티씨바이오 Composition containing clopidogrel free base

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156343A (en) * 1994-12-27 2000-12-05 Akzo Nobel N.V. Controlled release preparation
WO1998004541A1 (en) * 1996-07-25 1998-02-05 Dong A Pharmaceutical Co., Ltd. Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease
US6475521B1 (en) * 1998-03-19 2002-11-05 Bristol-Myers Squibb Co. Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2005023244A1 (en) * 2003-09-04 2005-03-17 Dong-A Pharmaceutical Co., Ltd. 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof
KR20050098440A (en) * 2004-04-07 2005-10-12 동아제약주식회사 Rapid-acting oral formulation of artemisia extract using solid dispersion, processing method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIJESH S. DAVE ET AL.: "Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation.", AAPS PHARMSCITECH, vol. 5, no. 2, 8 April 2004 (2004-04-08), pages e34, XP055351630 *

Also Published As

Publication number Publication date
WO2009008632A2 (en) 2009-01-15
KR20090004280A (en) 2009-01-12
KR101381999B1 (en) 2014-04-14

Similar Documents

Publication Publication Date Title
UA105229C2 (en) Pharmaceutical formulation
WO2009008632A3 (en) Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis
EP2684573A3 (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
GEP20135786B (en) Pyrrole compounds
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
MX2011012122A (en) Thiophene derivatives.
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
EP3492069A3 (en) Pharmaceutical compositions
WO2007109057A3 (en) Solid dosage form containing a taste masked active agent
MY139913A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
MX2011013069A (en) Solid compositions comprising 5-aminolevulinic acid.
MX337396B (en) Method of treating polycystic kidney diseases with ceramide derivatives.
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2010107807A3 (en) Compounds for treating inflammation and pain
TN2010000135A1 (en) Galenical formulations of organic compounds
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
UA102254C2 (en) Normal;heading 1;heading 2;heading 3;LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE
EP2361083A4 (en) Composition for treatment of epithelial tissue
EP2316420A8 (en) Method to reduce pain
UA122762C2 (en) ORAL COMPOSITION OF 9-[(2,2-DIMETHYLPROPYLAMINO)-METHYL]-MINOCYCLINE OR ITS SALTS, SOLID PRESSED DOSAGE FORM, COMPOSITION FOR INJECTIONS, APPLICATION AND METHOD OF PREPARATION OF THE PHARMACEUTICAL COMPOSITION
EP1935417A4 (en) Composition for use in prevention of hypoglycemic condition
WO2009095624A3 (en) Method for preparing dicaffeoylquinic acids and use thereof in combating aphids
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2008051527A3 (en) Sustained release of agents for localized pain management

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08778613

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08778613

Country of ref document: EP

Kind code of ref document: A2